Drug Profile
PD-1 knockout engineered T cells - Chengdu MedGenCell
Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Chengdu MedGenCell
- Developer Anhui Provincial Hospital; Chengdu MedGenCell; West China Hospital Sichuan University
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Gene silencing; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Lung cancer; Malignant melanoma
- No development reported Non-small cell lung cancer
Most Recent Events
- 17 Mar 2020 Chengdu MedGenCell completes a phase I trial in Non-small cell lung cancer (Metastatic disease, Late-stage disease) in China (Parenteral) (NCT02793856)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease) in China (Parenteral)
- 01 Jun 2018 Efficacy and adverse events data from a phase I trial in in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)